Nature Cancer

Article	Citations
Outcompeting neighbors for intestinal cancer initiation	616
Gut decisions in CAR T cell therapy	413
Untangling the threads of immunotherapy research	393
Author Correction: IL-17A-secreting γδ T cells promote resistance to CDK4/CDK6 inhibitors in HR+HER2− breast cancer via CX3CR1+ macrophages	392
Alzheimer’s drug turns macrophages against cancer	334
PARP11 interfer(on)es with CAR T cell efficacy	325
Enhancing childhood cancer targetability	311
Shooting for multiplexed pathology with Orion	302
Author Correction: Identification of a clinically efficacious CAR T cell subset in diffuse large B cell lymphoma by dynamic multidimensional single-cell profiling	275
Author Correction: Breaking the performance ceiling for neoantigen immunogenicity prediction	248
A macrophage-activated abscopal effect	236
Breaking frontiers with multidisciplinary cancer research	210
ZFP281 drives a mesenchymal-like dormancy program in early disseminated breast cancer cells that prevents metastatic outgrowth in the lung	208
An oncolytic circular RNA therapy	207
The proteasome regulator PSME4 modulates proteasome activity and antigen diversity to abrogate antitumor immunity in NSCLC	203
Evolutionary trajectories of IDH-mutant astrocytoma identify molecular grading markers related to cell cycling	201
Considering molecular alterations as pan-cancer tissue-agnostic targets	200
Landscape of prostate-specific membrane antigen heterogeneity and regulation in AR-positive and AR-negative metastatic prostate cancer	189
A low-coverage liquid biopsy for lung cancer	159
Author Correction: RIOK1 phase separation restricts PTEN translation via stress granules activating tumor growth in hepatocellular carcinoma	156
Breast cancer cells survive chemotherapy by activating targetable immune-modulatory programs characterized by PD-L1 or CD80	154
MALAT1 protects dormant tumor cells from immune elimination	135
Different niches for stem cells carrying the same oncogenic driver affect pathogenesis and therapy response in myeloproliferative neoplasms	132
Single-cell transcriptomic landscape deciphers olfactory neuroblastoma subtypes and intra-tumoral heterogeneity	131
A single-cell map of dynamic chromatin landscapes of immune cells in renal cell carcinoma	129

Repeated peripheral infusions of anti-EGFRvIII CAR T cells in combination with pembrolizumab show no efficacy in glioblastoma: a phase 1 trial	129
The cGAS–STING pathway and cancer	129
DePICting T cell–APC crosstalk in cancer	128
Beating cancer one carbon at a time	123
Expanding the options for KRAS inhibition	121
Palmitate oxidation drives a pro-metastatic post-translational modification	116
Impact of context-dependent autophagy states on tumor progression	112
Targeting PRMT9-mediated arginine methylation suppresses cancer stem cell maintenance and elicits cGAS-mediated anticancer immunity	111
Reply to: Ricolinostat is not a highly selective HDAC6 inhibitor	111
Stress granules shape metabolic reprogramming and drug resistance	109
Advancing therapeutics in small-cell lung cancer	108
The importance of being generous	103
Bone marrow progenitor-like cells against leukemia cure	102
Determinants of resistance and response to melanoma therapy	102
A targetable type III immune response with increase of IL-17A expressing CD4+ T cells is associated with immunotherapy-induced toxicity in melanoma	100
IKAROS and MENIN coordinate therapeutically actionable leukemogenic gene expression in MLL-r acute myeloid leukemia	97
A tumor-derived type III collagen-rich ECM niche regulates tumor cell dormancy	96
Shaping the microenvironment in peritoneal metastases	95
Reflecting on the golden age of cancer research	94
Adoptively transferred tumor-specific IL-9-producing cytotoxic CD8+ T cells activate host CD4+ T cells to control tumors with antigen loss	93
crossNN is an explainable framework for cross-platform DNA methylation-based classification of tumors	93
The labors of referees	89
Cancer-derived mitochondria fuel fibroblasts to become pro-tumorigenic	88
Sarcoma ecotypes determine immunotherapy benefit	87
Antibody avidity meets multiple myeloma	87
Circadian regulation of cancer stem cells and the tumor microenvironment during metastasis	87
Thriving in diverse ecosystems	86
Inflammation meets translation in AML	86
A multiomic atlas identifies a treatment-resistant, bone marrow progenitor-like cell population in T cell acute lymphoblastic leukemia	86
A quick guide for clinical oncology	86
Discovery of potent and selective HER2 inhibitors with efficacy against HER2 exon 20 insertion-driven tumors, which preserve wild-type EGFR signaling	85
Sex-specific gut microbiota and neutrophil senescence in bladder cancer	85
Author Correction: Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma	83
LAG-3 and PD-1 blockade raises the bar for melanoma	83
Evolving landscape of nasopharyngeal carcinoma therapy	82
Innate immunity drives epithelial cell plasticity during prostate tumor formation	82
INPP5A phosphatase is a synthetic lethal target in GNAQ and GNA11-mutant melanomas	82
A comeback for checkpoint inhibition in multiple myeloma	82
Loss of the receptors ER, PR and HER2 promotes USP15-dependent stabilization of PARP1 in triple-negative breast cancer	81
Proteogenomic landscape of human pancreatic ductal adenocarcinoma in an Asian population reveals tumor cell-enriched and immune-rich subtypes	80
ALK peptide vaccination restores the immunogenicity of ALK-rearranged non-small cell lung cancer	80
Clinical implementation of artificial-intelligence-assisted detection of breast cancer metastases in sentinel lymph nodes: the CONFIDENT-B single-center, non-randomized clinical trial	79
Integrative single-cell analysis of human colorectal cancer reveals patient stratification with distinct immune evasion mechanisms	79
Direct and selective pharmacological disruption of the YAP–TEAD interface by IAG933 inhibits Hippo-dependent and RAS–MAPK-altered cancers	78
Cycling back to folate metabolism in cancer	78
Efficacy of pembrolizumab and vorinostat combination in patients with recurrent and/or metastatic squamous cell carcinomas: a phase 2 basket trial	77
Concurrent inhibition of tumor growth and metastasis by a lipidated nanophotosensitizer tracing and disabling tumor extracellular vesicles	76
MCL1 inhibitor BRD-810 kills cancer cells while minimizing risk of cardiotoxicity	75
Regulatory T cells play a crucial part in radio-immunotherapy resistance of brain tumors	74
Immunosuppressive dura-derived macrophages in leptomeningeal metastasis	72

Bispecific antibodies seek out colon cancer stem cells	71
Radioligand cancer therapy comes to the fore	71
Building a translational cancer dependency map for The Cancer Genome Atlas	68
CHD1 status drives divergent metabolic pathways in SPOP-mutant prostate cancer	68
Radiation sparks a dark side in neutrophils	67
Multimodal data integration improves immunotherapy response prediction	66
Immunotargeting of a recurrent AML-specific neoantigen	65
Multiregion sampling of de novo metastatic prostate cancer reveals complex polyclonality and augments clinical genotyping	65
Dual inhibition of EGFR and PI3K with a single drug	65
A phase II study of talazoparib monotherapy in patients with wild-type BRCA1 and BRCA2 with a mutation in other homologous recombination genes	64
Differential chromatin accessibility and transcriptional dynamics define breast cancer subtypes and their lineages	64
How AI agents will change cancer research and oncology	64
First-in-class ultralong-target-residence-time p38α inhibitors as a mitosis-targeted therapy for colorectal cancer	61
Three-dimensional imaging mass cytometry for highly multiplexed molecular and cellular mapping of tissues and the tumor microenvironment	61
PD-1 instructs a tumor-suppressive metabolic program that restricts glycolysis and restrains AP-1 activity in T cell lymphoma	60
Selective targeting of malignant T cells	60
Author Correction: Ectopic JAK–STAT activation enables the transition to a stem-like and multilineage state conferring AR-targeted therapy resistance	60
GEMys homing in on metastasis	60
The Cancer Surfaceome Atlas integrates genomic, functional and drug response data to identify actionable targets	59
Targeting BRCA-mutated tumors in mitosis	59
LCOR mediates interferon-independent tumor immunogenicity and responsiveness to immune-checkpoint blockade in triple-negative breast cancer	59
AKTing on XPO1 inhibition in AML	59
Highlights from the 2025 ASCO Annual Meeting	58
The tumor microenvironment’s role in the response to immune checkpoint blockade	57
Protein-level mutant p53 reporters identify druggable rare precancerous clones in noncancerous tissues	57
The dopamine transporter antagonist vanoxerine inhibits G9a and suppresses cancer stem cell functions in colon tumors	57
Macrophage mitochondrial fission improves cancer cell phagocytosis induced by therapeutic antibodies and is impaired by glutamine competition	57
Threonine fuels glioblastoma through YRDC-mediated codon-biased translational reprogramming	56
Bispecific chimeric T cell receptors tackle tumor heterogeneity	56
BRD-810 is a highly selective MCL1 inhibitor with optimized in vivo clearance and robust efficacy in solid and hematological tumor models	55
Single-cell analyses implicate ascites in remodeling the ecosystems of primary and metastatic tumors in ovarian cancer	55
The pro-oncogenic noncanonical activity of a RAS•GTP:RanGAP1 complex facilitates nuclear protein export	55
Single-cell meta-analyses reveal responses of tumor-reactive CXCL13+ T cells to immune-checkpoint blockade	54
Single-cell analysis and functional characterization uncover the stem cell hierarchies and developmental origins of rhabdomyosarcoma	54
Identification of a clinically efficacious CAR T cell subset in diffuse large B cell lymphoma by dynamic multidimensional single-cell profiling	54
Epigenetic plasticity in PDAC	54
Advances in antibody-based therapy in oncology	54
Anything to declare?	54
Myeloma evades T cell-engaging therapies	53
An antisense RNA promotes breast cancer metastasis via upregulation of NQO1	53
Author Correction: Anti-CTLA-4 antibodies drive myeloid activation and reprogram the tumor microenvironment through FcγR engagement and type I interferon signaling	53
Metabolic symbiosis in pancreatic cancer	53
Neoadjuvant immunotherapy marks a new era in oncology	53
Author Correction: An inflammatory state remodels the immune microenvironment and improves risk stratification in acute myeloid leukemia	52
Author Correction: Acquired resistance to a GPRC5D-directed T-cell engager in multiple myeloma is mediated by genetic or epigenetic target inactivation	52
Estrogen receptor-positive breast cancer subtypes show differential macrophage functions	51
SETD2 loss perturbs the kidney cancer epigenetic landscape to promote metastasis and engenders actionable dependencies on histone chaperone complexes	49
In vivo macrophage engineering for renal cancer therapy	49
An unexpected career in cancer metabolism	49
Author Correction: Autotaxin–lysolipid signaling suppresses a CCL11–eosinophil axis to promote pancreatic cancer progression	48
There are gremlins in prostate cancer	47
Innate immunity and the NF-κB pathway control prostate stem cell plasticity, reprogramming and tumor initiation	47
p53 at the crossroads of tumor immunity	47
Dual modulation of cytotoxic and checkpoint receptors tunes the efficacy of adoptive Delta One T cell therapy against colorectal cancer	47
Sarcoma microenvironment cell states and ecosystems are associated with prognosis and predict response to immunotherapy	46
Clonal origin of KMT2A wild-type lineage-switch leukemia following CAR-T cell and blinatumomab therapy	46
Targeting ADAR1 with a small molecule for the treatment of prostate cancer	46
Ricolinostat is not a highly selective HDAC6 inhibitor	46
P2RY2-AKT activation is a therapeutically actionable consequence of XPO1 inhibition in acute myeloid leukemia	46
An anti-PD-1–GITR-L bispecific agonist induces GITR clustering-mediated T cell activation for cancer immunotherapy	45
Tumor evolution metrics predict recurrence beyond 10 years in locally advanced prostate cancer	45
Clinical and translational attributes of immune-related adverse events	45
A single-cell atlas of glioblastoma evolution under therapy reveals cell-intrinsic and cell-extrinsic therapeutic targets	45
Circumventing the roadblocks to targeting EGFR-driven cancers	45
Author Correction: Loss of MAT2A compromises methionine metabolism and represents a vulnerability in H3K27M mutant glioma by modulating the epigenome	44
PD-L2 expression in senescent cancer cells limits tumor clearance after chemotherapy	44
A new sophistication for breast cancer PDXs	44
Mitochondrial DNA mutation enhances sensitivity to immunotherapy in melanoma	44
Unique structural configuration of EV-DNA primes Kupffer cell-mediated antitumor immunity to prevent metastatic progression	43
Masking T cell engagers mitigates on-target off-tumor activity	43
Breaking the performance ceiling for neoantigen immunogenicity prediction	42
Overcoming extracellular vesicle-mediated fratricide improves CAR T cell treatment against solid tumors	42
CAR T cell therapy: looking back and looking forward	42
A randomized, non-comparative phase 2 study of neoadjuvant immune-checkpoint blockade in retroperitoneal dedifferentiated liposarcoma and extremity/truncal undifferentiated pleomorphic sarcoma	41
UnitedMet harnesses RNA–metabolite covariation to impute metabolite levels in clinical samples	41
Tumor-intrinsic sensitivity to the pro-apoptotic effects of IFN-γ is a major determinant of CD4+ CAR T-cell antitumor activity	40
Targeting PARP11 to avert immunosuppression and improve CAR T therapy in solid tumors	40
Multiomics in primary and metastatic breast tumors from the AURORA US network finds microenvironment and epigenetic drivers of metastasis	40
A reversible SRC-relayed COX2 inflammatory program drives resistance to BRAF and EGFR inhibition in BRAFV600E colorectal tumors	40
Understanding the biology of lung cancer brain metastases	40

TIGIT and PD-L1 co-blockade promotes clonal expansion of multipotent, non-exhausted antitumor T cells by facilitating co-stimulation	39
FLASH radiation reprograms lipid metabolism and macrophage immunity and sensitizes medulloblastoma to CAR-T cell therapy	39
Tumor-associated macrophages restrict CD8+ T cell function through collagen deposition and metabolic reprogramming of the breast cancer microenvironment	39
CD8+ T cell killing of MHC class I–deficient tumors	39
Glutaminase inhibition in combination with azacytidine in myelodysplastic syndromes: a phase 1b/2 clinical trial and correlative analyses	39
Leveraging the potential for deintensification in cancer care	38
CD103+ regulatory T cells underlie resistance to radio-immunotherapy and impair CD8+ T cell activation in glioblastoma	38
Spatially resolved transcriptomics and graph-based deep learning improve accuracy of routine CNS tumor diagnostics	38
Communicating with respect	38
Harnessing the microbiome to restore immunotherapy response	38
Temporal single-cell tracing reveals clonal revival and expansion of precursor exhausted T cells during anti-PD-1 therapy in lung cancer	38
The meaning of impact	38
CD4+ CAR T cells — more than helpers	37
Artificial intelligence for prostate cancer diagnostics	36
Therapeutic targeting of the mevalonate–geranylgeranyl diphosphate pathway with statins overcomes chemotherapy resistance in small cell lung cancer	36
Leveraging translational insights toward precision medicine approaches for brain metastases	35
Near-infrared optogenetic engineering of bacteria for cancer therapy	34
Insight from the ESMO Targeted Anticancer Therapies Congress 2025	34
Acute lymphoblastic leukemia displays a distinct highly methylated genome	34
Genomic and immune signatures predict clinical outcome in newly diagnosed multiple myeloma treated with immunotherapy regimens	34
SWIFT-seq enables comprehensive single-cell transcriptomic profiling of circulating tumor cells in multiple myeloma and its precursors	34
EZH2 inhibition remodels the inflammatory senescence-associated secretory phenotype to potentiate pancreatic cancer immune surveillance	34
Global loss of promoter–enhancer connectivity and rebalancing of gene expression during early colorectal cancer carcinogenesis	33
Efficacy and tolerability of neoadjuvant therapy with Talimogene laherparepvec in cutaneous basal cell carcinoma: a phase II trial (NeoBCC trial)	33
Radiopharma pipeline builds ahead of key data	32
Commensal metabolite boosts chemotherapy	31
The aging lung reawakens dormant tumor cells	31
Fibrotic tumors tune metabolism for immune evasion	31
Disparities, aging and childhood cancer	31
Author Correction: Cytokine release syndrome-like serum responses after COVID-19 vaccination are frequent and clinically inapparent under cancer immunotherapy	31
‘IL-2Rα-biased’ IL-2 for cancer immunotherapy	31
The rapidly evolving paradigm of neoadjuvant immunotherapy across cancer types	31
Cytidine deaminases APOBEC3C and APOBEC3D promote DNA replication stress resistance in pancreatic cancer cells	30
Melanoma-derived small extracellular vesicles induce lymphangiogenesis and metastasis through an NGFR-dependent mechanism	29
Context-dependent tumor-suppressive BMP signaling in diffuse intrinsic pontine glioma regulates stemness through epigenetic regulation of CXXC5	29
Integrative analysis of risk factors for immune-related adverse events of checkpoint blockade therapy in cancer	29
The landscape of T cell antigens for cancer immunotherapy	29
Targeting the histone reader ZMYND8 inhibits antiandrogen-induced neuroendocrine tumor transdifferentiation of prostate cancer	29
ISB 2001 trispecific T cell engager shows strong tumor cytotoxicity and overcomes immune escape mechanisms of multiple myeloma cells	29
Probing clonal dynamics with single-cell genomics	28
The growing threat of cyberwarfare in cancer healthcare	28
Author Correction: Safety and feasibility of 4-1BB co-stimulated CD19-specific CAR-NK cell therapy in refractory/relapsed large B cell lymphoma: a phase 1 trial	28
Targeting HIF-1 to treat AML	28
Stargazing through the lens of AI in clinical oncology	28
The two sides of the γδ T cell coin	27
CAR T cell therapy for multiple myeloma	27
Not a generative AI–generated Editorial	27
Bicarbonate transport as a vulnerability in pancreatic cancer	27
Checking immunotoxicity risks of checkpoint blockade	27
Remodeling cyclophilin A to target KRAS	27
T cells lead the charge against solid tumors	26
Imetelstat-mediated alterations in fatty acid metabolism to induce ferroptosis as a therapeutic strategy for acute myeloid leukemia	26
Network-based assessment of HDAC6 activity predicts preclinical and clinical responses to the HDAC6 inhibitor ricolinostat in breast cancer	26
Publisher Correction: Cancer’s new normal	26
Safety and feasibility of 4-1BB co-stimulated CD19-specific CAR-NK cell therapy in refractory/relapsed large B cell lymphoma: a phase 1 trial	26
LncRNA Malat1 suppresses pyroptosis and T cell-mediated killing of incipient metastatic cells	26
Checkpoint blockade regulates T cell fate by supporting co-stimulation	26
Resistance is futile with fourth-generation EGFR inhibitors	26
ERK1/2 phosphorylation predicts survival following anti-PD-1 immunotherapy in recurrent glioblastoma	25
Tumor-specific cholinergic CD4+ T lymphocytes guide immunosurveillance of hepatocellular carcinoma	25
Phenotypic diversity of T cells in human primary and metastatic brain tumors revealed by multiomic interrogation	24
Radiotherapy in combination with CD47 blockade elicits a macrophage-mediated abscopal effect	24
Selective multi-kinase inhibition sensitizes mesenchymal pancreatic cancer to immune checkpoint blockade by remodeling the tumor microenvironment	24
The craft (and art) of scientific writing	23
The editors’ point of view	23
A roadmap of therapeutic strategies for patients with multiple myeloma	23
Neoadjuvant chemotherapy enriches for drug-tolerant persisters in PDAC	23
Neutrophils determine immunotherapy success	23
APOBEC3A drives STING-dependent metastasis	23
SIGLEC9 tips the myeloid balance in glioblastoma	22
Mini colons to study cancer ex vivo	22
Keeping brain metastases dormant	22
Exploiting HLA-DR mismatches for CAR therapy in acute myeloid leukemia	22
Inferring early genetic progression in cancers with unobtainable premalignant disease	21
A designer peptide against the EAG2–Kvβ2 potassium channel targets the interaction of cancer cells and neurons to treat glioblastoma	21
Understanding inequities in precision oncology diagnostics	21
Characterization of cis-regulatory elements and functional variants in colorectal cancer using epigenomics and CRISPRi screenings	21
Combination of pembrolizumab and radiotherapy induces systemic antitumor immune responses in immunologically cold non-small cell lung cancer	21
An in vitro-transcribed circular RNA targets the mitochondrial inner membrane cardiolipin to ablate EIF4G2+/PTBP1+ pan-adenocarcinoma	20
Cell type and gene expression deconvolution with BayesPrism enables Bayesian integrative analysis across bulk and single-cell RNA sequencing in oncology	20
Multipotent lineage potential in B cell acute lymphoblastic leukemia is associated with distinct cellular origins and clinical features	20
Blocking methionine catabolism induces senescence and confers vulnerability to GSK3 inhibition in liver cancer	20
A T cell receptor targeting a recurrent driver mutation in FLT3 mediates elimination of primary human acute myeloid leukemia in vivo	20
Targeting TAK1 in microglia to treat CAR T cell neurotoxicity	20
PD-1 defines a distinct, functional, tissue-adapted state in Vδ1+ T cells with implications for cancer immunotherapy	20
Hallmarks of artificial intelligence contributions to precision oncology	20
Inhibition of ADAM9 promotes the selective degradation of KRAS and sensitizes pancreatic cancers to chemotherapy	19
Glutamine analogs for pancreatic cancer therapy	19
A Gremlin 1-expressing splenic niche cell population restrains chronic myeloid leukemia by antagonizing the BMP pathway	19
Selective deficiency of mitochondrial respiratory complex I subunits Ndufs4/6 causes tumor immunogenicity	19
Somatic evolution of marine transmissible leukemias in the common cockle, Cerastoderma edule	19
Mesenchymal and adrenergic cell lineage states in neuroblastoma possess distinct immunogenic phenotypes	19
Starfish infers signatures of complex genomic rearrangements across human cancers	19
Integrated multiomic profiling of breast cancer in the Chinese population reveals patient stratification and therapeutic vulnerabilities	18
Mind the GAP(43) for mitochondria transfer to glioblastomas	18